Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

857
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
857
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

1.0K
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
1.0K
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

468
Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
468
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

686
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
686
Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

258
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
258
Gastritis III: Clinical Manifestations and Management01:23

Gastritis III: Clinical Manifestations and Management

872
The clinical manifestations of gastritis can vary depending on the cause and type of gastritis, but some common symptoms may include the following.
Clinical manifestations of acute gastritis
The patient with acute gastritis may have a rapid onset of symptoms, such as epigastric pain or discomfort, dyspepsia, anorexia, hiccups, or nausea and vomiting, which can last from a few hours to a few days. Erosive or hemorrhagic gastritis may cause bleeding, which may manifest as blood in vomit or as...
872

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Phage intervention improves colitis and response to corticosteroids by attenuating virulence of Crohn's disease-associated bacteria.

Science translational medicine·2026
Same author

Exome sequencing directly implicates 68 genes in inflammatory bowel disease.

medRxiv : the preprint server for health sciences·2026
Same author

Antibiotics treatment promotes squamocolumnar junction tumor progression via tumor immune evasion in K19-Wnt1/C2mE mice fed high-fat diet and acidic bile salts.

American journal of physiology. Gastrointestinal and liver physiology·2026
Same author

Fecal Microbiota Transplantation for Symptom Improvement in Patients With Irritable Bowel Syndrome: Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Gastroenterology·2026
Same author

Comparative Performance of Artificial Intelligence-Based Computer-Aided Detection Systems for Colorectal Polyps: A Systematic Review and Network Meta-Analysis.

Digestive endoscopy : official journal of the Japan Gastroenterological Endoscopy Society·2026
Same author

Treatment and prognosis of proximal humerus fracture in older adults: a retrospective cohort study using health insurance claims database.

BMC geriatrics·2026

Related Experiment Video

Updated: Nov 30, 2025

Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment
03:25

Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment

Published on: December 27, 2024

1.3K

Who Needs Gastroprotection in 2020?

Takeshi Kanno1,2, Paul Moayyedi2,3

  • 1Division of Gastroenterology, Tohoku University Hospital, 1-1 Seiryo-machi, Aoba-ku, Sendai, Miyagi 980-8575 Japan.

Current Treatment Options in Gastroenterology
|November 17, 2020
PubMed
Summary

Peptic ulcer disease (PUD) can be reduced in patients taking non-steroidal anti-inflammatory drugs (NSAIDs) by testing for and treating Helicobacter pylori. Proton pump inhibitors (PPIs) also help prevent PUD in high-risk individuals.

Keywords:
Helicobacter pyloriNon-steroidal anti-inflammatory drugsPeptic ulcer diseaseProton pump inhibitorRisk-benefit

More Related Videos

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring
06:46

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring

Published on: December 14, 2020

3.1K

Related Experiment Videos

Last Updated: Nov 30, 2025

Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment
03:25

Author Spotlight: Exploring Non-Pharmacological Therapies for Chronic Respiratory Diseases — Linking Intestinal Microbiome Insights to COPD Treatment

Published on: December 27, 2024

1.3K
Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring
06:46

Simultaneous Laryngopharyngeal and Conventional Esophageal pH Monitoring

Published on: December 14, 2020

3.1K

Area of Science:

  • Gastroenterology
  • Pharmacology

Background:

  • Peptic ulcer disease (PUD) is a known complication of non-steroidal anti-inflammatory drug (NSAID) use.
  • Stress ulcers are a concern in intensive care unit (ICU) patients, and PUD affects those on anticoagulation therapy.

Purpose of the Study:

  • To review the efficacy of Helicobacter pylori (H. pylori) eradication and proton pump inhibitors (PPIs) in preventing NSAID-induced PUD.
  • To identify high-risk patient groups for PUD and evaluate current prevention strategies.

Main Methods:

  • Review of clinical trials and evidence regarding H. pylori eradication and PPI use for PUD prevention.
  • Analysis of risk factors for PUD development and complications.

Main Results:

  • H. pylori eradication significantly reduces PUD in NSAID patients.
  • PPIs are effective in reducing PUD in NSAID patients, ICU patients, and those on anticoagulants.
  • Increasing age, prior PUD history, and comorbidities are key risk factors for PUD.

Conclusions:

  • H. pylori test and treat strategies should be considered for older patients initiating NSAIDs.
  • PPIs should be prescribed for patients at high risk of developing PUD or its complications.